GSK shares fell more than 5% after US health officials narrowed their recommendation for the respiratory syncytial virus vaccine to younger ages and higher-risk patients.
GSK shares fell more than 5% after US health officials narrowed their recommendation for the respiratory syncytial virus vaccine to younger ages and higher-risk patients.
